Review

Astrocytes in Alzheimer’s disease: pathological significance and molecular pathways

Pranav Preman1,2,†, Maria Alfonso-Triguero3,4†, Elena Alberdi3,4, Alexej Verkhratsky3,6,7,* and Amaia M Arranz3,7,*

1 VIB Center for Brain & Disease Research, Leuven, Belgium.
2 Laboratory for the Research of Neurodegenerative Diseases, Department of Neurosciences, Leuven Brain Institute (LBI), KU Leuven (University of Leuven), Leuven, Belgium.
3 Achucarro Basque Center for Neuroscience, Leioa, Spain.
4 Department of Neurosciences, Universidad del País Vasco (UPV/EHU)
5 Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 48940 Leioa, Spain.
6 Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
7 Ikerbasque Basque Foundation for Science, Bilbao, Spain.

†These authors contributed equally.
*Correspondence: amai.a.arranz@achucarro.org and Alexej.Verkhratsky@manchester.ac.uk

Abstract: Astrocytes perform a wide variety of essential functions defining normal operation of the nervous system, and are active contributors to the pathogenesis of neurodegenerative disorders such as Alzheimer among others. Recent data provide compelling evidence that distinct reactive astrocyte states are associated with specific stages of Alzheimer’s disease. The advent of transcriptomics technologies enables rapid progress in the characterisation of such pathological astrocyte states. In this review, we provide an overview of the origin, main functions, molecular and morphological features of astrocytes in physiological as well as pathological conditions related to Alzheimer’s disease. We will also explore the main roles of astrocytes in the pathogenesis of Alzheimer’s disease and summarize main transcriptional changes and altered molecular pathways observed in astrocytes during the course of the disease.

Keywords: Astrocyte; Alzheimer’s disease; neurodegeneration; transcriptomics; RNA sequencing (RNA-seq), cellular states

1. INTRODUCTION

In 1856, Rudolf Virchow introduced the concept of neuroglia as a connective tissue of the brain and the spinal cord that holds together nervous elements (Virchow 1856). Glial cells have been in focus of research of many prominent neuroanatomists of the 19th century; in particular morphology of parenchymal glia characterized by stellate appearance when stained by Golgi technique has been minutely characterised (Chvátal and Verkhratsky 2018). These stellate cells received the name of astrocytes (αστρον κύτταρον; astron, star and kytos, a hollow vessel, later cell i.e. star-like cell) (von Lenhossék 1895). Rather prophetically, Lenhossék proposed to call all parenchymal glial cells "spongiocytes” and he only named a subpopulation of them as astrocytes. Astrocytes belong to the class of neural cells known as astrogia, which covers several differ-
ent cell types including astrocytes proper, radial astrocytes, velate astrocytes, tanyocytes, pituicytes, ependymocytes, choroid plexus cells and retinal pigment epithelial cells. Astrocytes are parenchymal homeostatic and defensive cells of the central nervous system (CNS). Recent data provide clear evidence that astrocytes actively contribute to the pathogenesis of neurodegenerative disorders, with particular role in Alzheimer’s disease, Parkinson disease, Huntington disease, multiple sclerosis and amyotrophic lateral sclerosis. In this review, we provide overview of the multifaceted roles of astrocytes in physiological as well as pathological conditions related to Alzheimer’s disease. We also explore mechanisms by which astrocytes contribute to Alzheimer’s and summarize main transcriptional changes and altered molecular pathways observed in astrocytes during the course of Alzheimer’s disease.

2. ASTROCYTES IN THE HEALTHY BRAIN

2.1. Origin, development and numbers

2.2. Origin

Astrocytes, similarly to neurones and oligodendroglia, originate from neuroepithelium-derived radial glial cells. At the beginning of astroglial lineage lie dedicated precursors that are produced by asymmetric division by radial glial cells. The bulk of astrocytes however emerges postnatally and the major source for astrogenesis is associated with symmetric division of differentiated astrocytes; this division was initially described by Ramon y Cajal in a form of twin astrocytes or “astrocitos gemelos” (Ramón y Cajal 1913). Astrocytes can also emerge from direct transformation of radial glia or differentiate from NG2 glial cells also known as oligodendrocyte precursors or OPCs (Fig. 1A) (Molofsky and Deneen 2015; Schitine et al. 2015). Intermediate glial progenitor cells, originated from asymmetric division of radial glia, generate immature astrocytes that migrate towards the cortical layers and proliferate through symmetric division. In layer I of the embryonic and neonatal cortex there are other type of neural progenitors that give rise to the astrocytes of superficial layers (I-IV) (Fig. 1A) (Verkhratsky and Nedergaard 2018).

2.3. Prenatal astrogenesis

In foetal brain development, gliogenesis follows neurogenesis. Molecular mechanisms that govern differentiation of astrocytes are mainly determined by the expression of two astrocytic genes: intermediate filament glial fibrillary acidic protein (GFAP) and calcium binding protein (S100β) (Guillemot 2007; He et al. 2005). Three signalling pathways, JAK-STAT, Notch and BMP-SMAD, determine the embryonic development of astrocytes. The IL-6 family of cytokines (CNTF, LIF, CT-1) are primarily responsible for initiating gliogenesis (Nakashima et al., 1999). This family activates the canonical JAK/STAT signalling pathway; activated STAT is responsible, together with the p300/CPB co-activator complex, for promoting transcription of astroglial genes to initiate formation of astrocytes (Freeman, 2010; He et al., 2005; Kanski et al., 2014; Urayama et al., 2013) (Fig. 1B). In the course of astrogenesis, JAK/STAT and Notch signalling pathways act synergistically: activation of JAK produces the release of Notch ligands to activate this pathway; Notch activity, on the other hand, induces the phosphorylation of STAT thus activating JAK/STAT cascade (Kanski et al. 2014) (Fig. 1B). Notch is also involved in the demethylation and, therefore, in epigenetic regulation of astrocytic genes during differentiation. In neurogenesis, the promoter of the astrocytic gene glial fibrillary acidic protein (GFAP) is epigenetically silenced through methylation by DNA methyl-
transferase I (DNMT1). When astrogenesis begins, Notch signalling pathway activates DNMT1 release, allowing GFAP transcription and astrogenesis. Epigenetic regulation of astrocytic genes is also regulated by JAK/STAT pathway since acetylation of histones by p300/CBP enhances the opening of chromatin (Kanski et al. 2014). Notch cascade also promotes astrogenesis by directly activating the GFAP promoter (Guillemot 2007). In addition, BMP ligands, members of the transforming growth factor beta (TGF-β) signalling ligands superfamily, bind to and activate their respective receptors inducing SMAD phosphorylation and its dimerisation with SMAD4. The SMAD-SMAD4 complex is a transcriptional activator of astrocytic genes such as GFAP and calcium-binding protein β (S100β) which promote astrogenesis (Fig. 1B). This astrogenesis signalling pathway has been described in progenitor cultures at embryonic day 14 and later; besides promoting astrogenesis this pathway suppresses neuronal and oligodendrocytic differentiation (Gross et al., 1996; Krencik et al., 2017; Nakashima et al., 2001; Qin et al., 2014). Both JAK-STAT and Notch pathways are also activated by BMP signalling (Nakashima et al., 2001; Takizawa et al., 2003).

2.4. Postnatal astrogenesis

The second, and the largest wave of astrogenesis occurs postnatally. During postnatal astrogenesis, approximately 50% of all astrocytes are generated from the symmetric division of differentiated astrocytes (Ge et al. 2012) (Fig. 1A). In this second wave, protoplasmic astrocytes are also generated by direct transformation of radial glia, which lose their apical processes; besides, astrocytes can arise from NG2 glial cells (Dimou et al. 2008; Du et al. 2020; Huang et al. 2019) (Fig. 1A). The importance of the BMP-SMAD signalling pathway in adult astrogenesis is well documented: inactivation of this pathway reduces the expression of astrocytic genes such as GFAP and S100β, and decreases the number of astrocytes (Qin et al. 2014). In contrast, the number of GFAP-positive astrocytes increases substantially in a mouse model overexpressing BMP (Gomes, Mehler, and Kessler 2003). More studies are needed to elucidate other potential signalling cascades involved in postnatal astrogenesis.

2.5. Astrocyte numbers

There is some controversy about the total number of astrocytes, and their proportion in different brain regions remains to be elucidated. Isotropic fractionation and quantitative unbiased stereology estimate that all glia accounts for ~40% of all cells in the human brain; the ratio of non-neuronal cells to neurons varies depending on the region (von Bartheld, Bahney, and Herculano-Houzel 2016; Sherwood et al. 2006), being 0.2:1 in the cerebellum, 3.7:1 in the cortex and up 7:1 in the spinal cord and 11:1 in the brain stem (Verkhratsky and Nedergaard 2018).

In different brain regions astrocytes account for 20-40% of the total glial population, suggesting that oligodendrocytes are slightly more numerous (von Bartheld et al. 2016; Verkhratsky and Nedergaard 2018). Stereology studies (without immunocytochemistry) on postmortem human brain samples report 75% oligodendrocytes, 20% astrocytes and 5% microglia in neocortex (Pelvig et al. 2008). In mouse cortex the ratio of astrocytes to neurones is around 0.2 (Keller, Erö, and Markram 2018).
2.5. Astrocyte functions in healthy brain

Astrocytes perform a wide variety of critical functions determining normal operation of the nervous tissue. Numerous receptors expressed in astrocytes allow them to sense neuronal activity (Verkhratsky 2010), activation of these receptors trigger astrocytic ionic signalling, mainly mediated by changes in cytosolic concentration of Ca^{2+} and...
Na⁺ (Rose and Verkhratsky 2016), which control a multitude of plasmalemmal "homeostatic" transporters (Verkhratsky and Rose 2020). These transporters are responsible for K⁺ buffering, clearance of neurotransmitters including glutamate, ATP, GABA, adenosine and endocannabinoids among others, maintaining synaptic transmission, preventing excitotoxicity and providing for neuroprotection (Vasile, Dossi, and Rouach 2017; Verkhratsky and Nedergaard 2018). These transporters specifically concentrate in distal astrogial processes that enwrap synaptic contacts; the perisynaptic membranous sheath form the astrogial cradle, essential for all aspects of synaptic function from synaptogenesis and synaptic maintenance to synaptic extinction (Verkhratsky and Nedergaard 2014). Astrocytes promote synaptogenesis by producing and secreting critically important factors such as cholesterol, glypicans, hevin and thrombospondins (Allen and Eroglu 2017; Baldwin and Eroglu 2017). They also control synapse elimination by direct phagocytosis (Lee et al. 2020) or by modulating microglia synaptic pruning in a complementary dependent process (Jung and Chung 2018). Astrocytic endfeet contact blood vessels and, together with endothelial cells and pericytes, create the blood-brain barrier (BBB) which separates the highly controlled brain microenvironment from the peripheral blood circulation (Sweeney et al. 2019). Astrocytes form a functional and anatomical link between the vasculature and the CNS parenchyma through the neurogliovascular unit (Liebner et al. 2018), regulate local blood flow and contribute to energy supply in the form of lactate to neurones (Nortley and Attwell 2017; Pellerin and Magistretti 2012). They store glycogen, which is metabolised to pyruvate and lactate, with the latter transported across the cell membrane and delivered to neighbouring neurones. Astrocytes are fundamental for operation of the lymphatic system, an organised pathway for elimination of soluble proteins, waste products, and excess extracellular fluid from the brain, in which clearance is facilitated by astrocytic aquaporin 4 (AQP4) water channels (Iliff et al., 2012; Nedergaard, 2013). Finally, they control extracellular space volume and are also in charge of the homeostatic maintenance of the CNS by transporting extracellular ions, protons and metabolites, and controlling levels of pH and water (Verkhratsky and Nedergaard 2018).

2.6. Astrocyte Diversity

Although belonging to the same class of neural cells and sharing same basic properties (such as high K⁺ permeability, expression of transporters providing for molecular homeostasis, ionic excitability, etcetera), there is a prominent inter- and intra-regional heterogeneity among astrocytic populations at both morphological and molecular levels, which translates into differential functional properties. Heterogeneity of astrocytes might be explained, at least in part, by their diverse place of birth and association to specific type of progenitors. Intrinsic programs within the astrocytic precursors and extrinsic signals from neighbouring cells can also influence the diversity.

2.7. Morphological subtypes of cortical astrocytes

There are four main morphologically distinct subtypes of astrocytes in the human neocortex while only two have been found in rodents:

Protoplasmic astrocytes represent the most abundant type of astroglia in the grey matter and are located in cortical layers II to VI (Oberheim et al. 2006). They are characterised by a small cell body, of approx. 10 µm in diameter with many large processes (up to 40 in humans, several in rodents). These processes extend radially from the soma, and many complex and fine lateral branches are born from them, defining the territory of astrocyte domain. Territorial domains of cortical protoplasmic astrocytes show very little (<5%) overlap (Bushong et al. 2002). The volume of human protoplasmic astrocytes is about 10 to 20 times greater than that of rodent astrocytes (Oberheim et al. 2009).
Interlaminar astrocytes are almost exclusively found in higher primates (although there are descriptions of rudimentary interlaminar astrocytes in mouse (Falcone et al. 2021)), and emerge at postnatal stages. Their somata are located in layer I of the cerebral cortex. These cell bodies are around 10 µm diameter; and several generally unbranched processes emanate from them. These processes are of two types: shorter fibres directed towards the cortex surface that contribute to the astrocytic network underneath the pia mater, and very long fibres that penetrate through the deep layers of the cortex (layers III-IV). Interlaminar astrocytes do not occupy specific territorial domains and overlap with their neighbours. They express markers of radial glia (Pax6, Sox2, and Nestin), as well as astrocytic markers GFAP, S100β, Aqp4, and GLAST in both rodents and hominids (Falcone et al. 2021). Grafting human iPSC-derived astrocyte progenitors in the mouse brain results in appearance of GFAP-positive interlaminar astrocytes in layer I of the mouse cortex (Fig. 2A). Although functions of interlaminar astrocytes remain enigmatic, their structure suggests an essential role in intra-cortical communication (Colombo, Quinn, and Puissant 2002; Oberheim et al. 2009; Oberheim et al. 2006; Sosunov et al. 2014).

Varicose-projection astrocytes are similarly found only in primate brains. These cells are located in cortical layers V to VI. Their numbers are low and they strongly express GFAP. They have several short and straight processes as well as one to five very long (up to 1 mm) processes that are usually straight, unbranched, and have numerous beads or varicosities distributed about 10 µm apart. Unlike protoplasmic astrocytes, they are not organised into well-defined spatial domains and their processes cross through domains of neighbouring astrocytes. Their functions are unclear, arguably varicose-projection astrocytes contribute to long-distance communication through cortical layers and even between grey and white matter (Oberheim et al. 2009; Oberheim et al. 2006; Sosunov et al. 2014).

Fibrous astrocytes reside in white matter tracts; human astrocytes are much larger than rodent ones. Fibrous astrocytes have a small round soma and straight nonbranched processes. Their fibres overlap, but their bodies do not; they are equidistant from each other. Their processes extend multiple finger-like cytoplasmic protrusions that are directed into the perinodal spaces of the surrounding axons. In addition, fibrous astrocytes contact blood vessels through their processes and endfeet, as do protoplasmic astrocytes (Kettenmann and Verkhratsky 2013; Oberheim et al. 2009; Oberheim et al. 2006).

While GFAP has proved to be a reliable marker of astrocytes in vitro, not all astrocytes are immunopositive for GFAP in physiological conditions. Regional differences are also reported with higher GFAP expression in hippocampal than in cortical, striatal or thalamic astrocytes (Escartin, Guillemaud, and Carrillo-de Sauvage 2019). For reliable characterisation of astrocytic subtypes, immunohistochemical morphometry must utilise additional markers, including cytosolic (such as S100b, glutamine synthetase, aldolase C, ALDH1L1) that allow a better visualisation of the morphological profiles. Astrogliaspecific fluorescent reporter mice (i.e. ALDH1L1-GFP), astroglia-specific Cre lines or intraglial injection of fluorescent dyes can also improve morphological characterisation (Jahn et al. 2018; Yu, Nagai, and Khakh 2020).

2.8. Molecular diversity and functional implications

The outbreak of new sequencing methodologies provides for remarkable expansion of our knowledge of molecular diversity of astrocytes. Specialised subpopulations of astrocytes have been recently identified across different brain regions by RNA sequencing in astrocyte-specific reporter mice (Chai et al. 2017; John Lin et al. 2017; Morel et al. 2017). While all astrocytes are strongly enriched in pan-glial gene signatures, each subpopulation shows a unique molecular profile across regions. Distinct sub-populations of astrocytes also exhibit differences in morphology, electrophysiology and calcium signalling (Chai et al. 2017; Morel et al. 2017). These sub-populations also differ in migratory
and proliferative capacities, synaptic coverage and ability to support synaptogenesis and neuronal growth and maturation (Chai et al. 2017; John Lin et al. 2017; Morel et al. 2017), further corroborating astrocyte diversity tailored to support specific brain regions. Even within a specific brain region, such as cortex, astrocytes in different layers show distinct morphological features, gene signatures, functional properties and cell-surface markers (Lanjakornsiripan et al. 2018; Morel et al. 2019), indicating the high adaptive potential of these cells.

Between and within-regional astrocyte diversity has recently been confirmed by single-cell RNA sequencing and in situ analyses. Molecularly distinct astrocytic subtypes have been described within the cortex, identifying superficial, mid and deep layer astrocyte gene profiles in a layer patterning that differs from those of neurons (Bayraktar et al. 2020). Moreover, up to five molecularly distinct astrocyte subtypes have been identified in mouse cortex and hippocampus, each showing specific morphologies and distinct Ca^{2+} dynamics (Batiuk et al., 2020), further highlighting region-dependent functional diversity.

In summary, astrocyte gene expression varies between as well as within brain regions, with astrocytes from each individual brain area showing a subtle and specific gene expression gradient. These molecular differences correlate with distinct morphological features both having functional implications that are beginning to emerge.

3. ASTROCYTES IN ALZHEIMER’S DISEASE

3.1. Major roles of astrocytes in Alzheimer’s disease

Alzheimer’s disease (AD) is characterised by amyloid-β accumulation (β-amyloid or senile plaques), formation of hyperphosphorylated tau neurofibrillary tangles, neuroinflammation, synaptic demise, neuronal death and brain dysfunction leading to severe cognitive impairment. The amyloid hypothesis originally postulated a linearity of progression according to β-amyloid accumulation, which subsequently led to formation of tangles and other pathological hallmarks (Selkoe and Hardy 2016). More recent observations demonstrated that such linear model needs to consider the contribution of different brain cells (Strooper and Karran 2016). Evolution of AD takes long time, with brain defences sustaining homeostasis for decades before cognitive disability becomes apparent in advanced stages of the disease (Strooper and Karran 2016). This cellular defensive phase represents the biological equivalent of preclinical AD (Dubois et al. 2016) and involves complex circular and parallel pathways and poorly characterised homeostatic responses associated with different types of brain cells (Frere and Slutsky 2018).

The role for glial cells, and for astrocytes in particular, in neuropathology of many neurodegenerative diseases is universally acknowledged (Verkhratsky et al. 2010; Verkhratsky, Zorec, and Parpura 2017). The risk of AD is associated with genes mainly expressed by glial cells, either astrocytes, microglia and/or oligodendrocytes (Arranz and De Strooper 2019). Apolipoprotein E (APOE), a major genetic risk factor in Late-Onset AD (LOAD), is mainly expressed in astrocytes in the healthy brain (Yu, Tan, and Hardy 2014) and contributes to accumulation of β-amyloid in the brain (Holtzman et al. 2000; Verghese et al. 2013). Other genes associated with AD such as Clusterin (CLU) and Fermitin family member 2 (FERMT2) are similarly predominantly expressed by astrocytes. Reactive astrogliosis is prominent in AD being an early event in human patients and in animal models, possibly even preceding the formation of β-amyloid plaques (Carter et al. 2012; Rodriguez-Vieitez et al. 2015, 2016; Scholl et al. 2015). These data suggest a crucial role of astrocytes in the pathogenesis of AD.
Morphological studies in post-mortem AD patient brains demonstrated close interaction between astrocytes and β-amyloid depositions (Serrano-Pozo et al. 2013) (Fig. 2B). It is however unclear how this close interaction translates into the disease progression. Astrocytes, when associated with senile plaques, become reactive with morphological hypertrophy manifested by thicker processes and increased expression of the intermediate filament proteins glial fibrillary acidic protein (GFAP), vimentin, nestin and synemin (Escartin et al. 2021). Reactive astrocytes are found in both human AD patient brains (Beach and McGeer 1988) and AD mice models (Fig. 2B) (Rodriguez et al. 2009; Verkhratsky et al. 2016). Pathological signals inducing astrogliosis in AD can be associated with damaged cells; β-amyloid by itself is a strong instigator of astrocyte reactivity. At molecular level, β-amyloid induction of astrogliotic remodelling is mediated by Ca\textsuperscript{2+} release from the endoplasmic reticulum; inhibition of the latter suppresses astrocytic reactivity (Alberdi et al. 2013). In AD, astrocytes undergo relatively mild isomorphic gliosis and astrocytic domains do not overlap, potentially indicating a defensive nature of the astrocytic response. Indeed, inhibition of astrogliosis exacerbates β-amyloid accumulation and histopathology in AD mice (Kraft et al. 2013). Reactive astrocytes in the vicinity of plaques display aberrant calcium dynamics (Agulhon et al. 2012; Kuchibhotla et al. 2009). Astrocyte Ca\textsuperscript{2+} hyperactivity could promote the release of detrimental factors, alter neuron-glial communication and impair synaptic transmission and plasticity (Frost and Li 2017; Verkhratsky, Rodriguez-Arellano, et al. 2017) (Fig. 3).

Besides substantial astrogliarial reactivity, atrophic astrocytes are also present in post-mortem brains of AD patients (Colombo et al. 2002; Hsu et al. 2018) and mouse models of AD (Verkhratsky et al. 2016). In particular, human AD brains are characterised by severe disruption or even complete disappearance of interlaminar astrocytes (Colombo et al. 2002). Atrophic astrocytes are characterised by reduced volume and thinner processes as revealed by morphometric analysis of cells immunolabelled with antibodies against GFAP, S100b (Yeh et al. 2011) and GS (Olabarria et al. 2011). In the 3xTg-AD mice model, atrophic astrocytes appear as early as 1-month age in the entorhinal cortex (EC) and the atrophy is sustained after 12 months of age when β-amyloid plaques begin to appear (Yeh et al. 2011). Similar astrogial atrophy has been described in other models of AD including 5xTG-AD mice, PDAPP-J20 transgenic mice and Swiss 3 (Beauquis et al. 2014; Diniz et al. 2017; Iram et al. 2016; Polis et al. 2018). Human astrocytes derived from induced pluripotent stem cells (iPSC) from patients with both familial and sporadic forms of AD also show atrophic phenotypes in vitro compared to control cells (Jones et al. 2017). While atrophy might lead to loss of astrocyte homeostatic functions and give rise to synaptic dysfunction, increased excitability and/or damage of the BBB, (Fig. 3) very little functional data are available. Finally, neurodegenerative process may directly damage astrocytes resulting in clasmatodendrosis, characterised by fragmentation and disappearance of distal fine processes, along with swelling and vacuolation of the cell body (Chen et al. 2016) (Fig. 3).
Astrocytes could, in principle, involved in β-amyloid production as they upregulate β-secretase 1 and the amyloid precursor protein (APP) in the diseased brain (Frost and Li 2017), however no quantitative data points to astrocytes as the major source of β-amyloid. Astrocytes more likely participate in β-amyloid clearance and elimination by different mechanisms. Astrocytes express aquaporin 4 (AQP4) water channels in their vascular end-feet and play an essential role in the glymphatic system implicated in the clearance of β-amyloid (Iliff et al., 2012; Nedergaard, 2013) (Fig. 3). They also produce β-amyloid degrading proteases that cleave the peptide into smaller fragments. The metalloendopeptidases neprilysin (NEP), insulin-degrading enzyme (IDE), and endothelin-converting enzymes 1 and 2 (ECE1 and ECE2) are all expressed in astrocytes and contribute to the degradation of monomeric β-amyloid species (Ries and Sastre 2016). Astrocytes also express matrix metalloproteinases MMP-2 and MMP-9 which degrade both fibrillar and monomeric β-amyloid (Ries and Sastre 2016) (Fig. 3). Clearance of β-amyloid can be mediated by extracellular proteins APOE, Apol/Clusterin, α1-antichymotrypsin (ACT) and α2-macroglobulin (α2-M), all produced by astrocytes (Fig. 3); these proteins promote the transport of β-amyloid across the BBB to the circulation either alone or in association with LRP1 and VLDLR receptors (Ries and Sastre 2016). Recent studies report that iPSC-derived human astrocytes and mouse astrocytes expressing APOE4 are less efficient in clearing β-amyloid than those expressing APOE3 (Lin et al. 2018; Simonovitch et al. 2016). In addition to β-amyloid clearance, APOE also regulates β-amyloid seeding with APOE4 more potently affecting seed formation than APOE3. APOE affects plaque size and neuritic dystrophy without having much influence on total amyloid load (Huynh et al. 2017; Liu et al. 2017). Expression of APOE4 also leads to degeneration of pericytes thus facilitating breakdown of the BBB further contributing to cognitive impairment in APOE4 carriers (Montagne et al. 2020).
In AD, reactive astrocytes interact with neurones, microglia and oligodendrocytes by releasing feed-forward signals and contributing to the vicious cycle that leads to neurodegeneration. Of note, β-amyloid can activate the NF-κB pathway in astrocytes, which leads to the release of the complement protein C3 (Fig. 3). The C3 binding to the microglial receptor C3aR alters β-amyloid phagocytosis while the C3 binding to the neuronal receptor C3aR disrupts dendritic morphology and network function, both effects contributing to AD pathogenesis (Lian and Zheng 2016). Both NF-κB and C3 cascades are activated in human AD brain and in AD mouse models (Lian et al. 2015; Liddelow et al. 2017). Microglia can also activate astrocytes by secreting specific cytokines (IL-1α, TNFα, and C1q) (Liddelow et al. 2017). This type of reactive astrocytes upregulate classical complement cascade genes including C3 and lose ability to promote synapse formation and function, and to phagocytose synapses and myelin debris (Liddelow et al. 2017). About 60% of the astrocytes in the prefrontal cortex of AD patients are C3-expressing astrocytes (Liddelow et al. 2017) and could contribute to neuronal damage; although further analyses are needed for confirmation. In AD, reactive astrocytes participate in shifting the excitation-inhibition balance through secretions of GABA. In the healthy brain, astrocytes do not contribute much to GABA production, however, in AD GABA starts to be synthesised by astrocytes through putrescine-MAO-B pathway (Jo et al. 2014). In this way, reactive astrocytes start to secrete GABA thus increasing inhibition, likely to be a defensive response against neuronal hyperexcitability that seems to be a universal result of AD progression (Ghatak et al. 2019; Garaschuk and Verkhratsky 2019). Increase in MAO-B expression in astrocytes, which accompanies AD, also results in a hyperproduction of hydrogen peroxide that may instigate neuronal damage and death (Chun et al. 2020).

Astrocyte potentially contribute to neuronal damage in other human neurodegenerative diseases such as Parkinson’s disease (Gu et al. 2010; Solano et al. 2008; Yun et al. 2018), Huntington’s disease (Diaz-Castro et al. 2019; Tong et al. 2014), multiple sclerosis (Alami et al. 2018; Wheeler and Quintana 2019) and amyotrophic lateral sclerosis (Di Giorgio et al. 2007), indicating a direct contribution of astrocytes to a general programme of neurodegeneration. Most probably, astrocyte states and phenotypes differ among diseases, and even at different stages of a specific disease; further analyses are needed to dissect specific molecular pathways related to specific disease stages.

At the same time, astrocytes can exert neuroprotection at different stages of AD. Both astroglisis and microglisis in response to β-amyloid increase glial secretion of transforming growth factor β (TGF-β) (Fig. 3). TGF-β protects neurones from β-amyloid toxicity and enhances β-amyloid clearance by microglia (Diniz et al. 2017; Lian and Zheng 2016). Moreover, astrocytes surrounding β-amyloid plaques demonstrate phagocytic activity and are able to phagocytose neuritic dystrophies in both mouse models and AD patients brains, further suggesting beneficial roles of astrocytes in AD (Gomez-Arboledas et al. 2018).

These data show that astrocytes actively contribute to the pathogenesis of AD. At the same time many questions remain to be addressed. What astrogial states phenotypes are found at different stages of AD? How do astrocyte states phenotypes differ between brain regions, which are known to have different vulnerability of AD? How do astrocytes crosstalk with other brain cells? Are they able to promote neurodegeneration? How do AD risk genes modulate astroglia responses in AD? New methodologies such as RNA sequencing and spatial transcriptomics in combination with the use of human iPSC-derived models and CRISPR-based studies are providing deeper understanding into how astrocytes evolve during the course of AD.
Contribution of astrocytes to Alzheimer’s disease

During the course of AD, astrocytes interact with neurones, microglia and other CNS cells by releasing feed-forward signals and contributing to the vicious cycle leading to neurodegeneration. While reactive astrocytes potentially have both protective and detrimental functions during the course of AD, atrophic astrocytes might lose their homeostatic functions. Astrocyte contribution to β-amyloid degradation and clearance will also influence AD progression.

3.2. Astrocyte genes and altered molecular pathways in AD

RNA sequencing approaches are providing novel information about astrocyte states and soon we will be able to relate these states to different stages of AD. RNA sequencing analyses on acutely isolated mouse astrocytes revealed increased expression of inflammatory response genes (Cst7, Ccl4, Il1b, Clec7a, Tyrobp) and reduced expression of neuronal support genes (Hes5) and cholesterol biosynthesis genes (Tm7sf2, Cyp51, Mod) in astrocytes from AD model mice (APPswe/PS1dE9) compared to healthy controls (Orre et al. 2014) (Table 1). When looking at specific genes, mouse astrocytes upregulate Gfap, Bcl3, Serpina3n, Cyb5r2, Chil4, Bdkrb2, Rnase4 and the complement cascade genes C4a, C4b in AD model mice (PS2APP and APP/PS1) compared to control mice (Pan et al. 2020; Srinivasan et al. 2016) (Table 1). In AD and healthy human post-mortem brains, transcriptional analyses of isolated astrocytes from different regions revealed differential expression of genes in pathways regulating cytoskeleton (MYO6, KIF21A, ACTNB), cell signalling (IGF1R, PIK3R1, MAP3K12), tight junctions (GJC1, ZO1, TJAPI) (Simpson et al. 2011), and lipid metabolism (ACOT1, ACOT2) (Mills et al. 2013), as well as dysregulation of mitochondria-related genes (TRMT61B, FASTKD2, NDUF4L2) and immune response genes (CLU, C3, CD74) (Sekar et al. 2015) (Table 1). Overall, these data support astrocyte-specific contributions to AD mainly related to lipid metabolism, cholesterol biosynthesis, immune responses, and neuronal support, highlighting the importance of astrocyte activity in the neurodegenerative process.
While RNA sequencing of pooled astrocytes robustly corroborates the contribution of these cells to AD pathophysiology, it only captures expression of genes in grouped cells thus yielding population averages. Such transcriptome analyses can be affected by alterations in cell type composition of diseased vs. control samples and is unable to detect specific cell states, or changes in gene expression that occur in cell subsets. Therefore, single-cell or single-nuclei RNA sequencing and spatial transcriptomics are providing deeper insight in how cellular states evolve during AD progression.

Single-nucleus RNA sequencing of mouse astrocytes identified sub-populations of GFAP-low and GFAP-high astrocytes in both WT and AD mice (5xFAD); in addition, a unique cluster of disease-associated astrocytes (DAA) was detected in the AD mice (Habib et al. 2020). The DAA cluster was enriched in Gfap, Serpina3n, Ctsb, Apoe and Clu among other genes (Table 1). While Apoe and Clu are known AD risk genes involved in amyloid processing, Ctsb encodes a lysosomal protease, Cathepsin B, linked to proteolytic processing of the amyloid precursor protein (APP), and Serpina3n encodes a protease inhibitor associated with increased β-amyloid accumulation. Serpina3n has also been identified in astrocytes from other AD model mice (Pan et al., 2020; Srinivasan et al., 2016) thus becoming a prime candidate for future investigations. Most of the detrimental astrocytic signature genes described in previous studies (Liddelow et al. 2017) are expressed by DAAs. Moreover, there are up to 18 genes shared by DAAs and disease-associated microglia (Keren-Shaul et al. 2017), including Apoe, Ctsb, Ctsd and Ctsl, all encoding proteins involved in AD pathogenesis suggesting a general transcriptional program shared across cell types in AD. DAAs appear at early stages of AD and become more abundant as disease progresses suggesting that they not only respond to disease but also modulate disease course. Similar "pathological" astrocytes also emerge in aged WT mice and in ageing human brains (Habib et al. 2020), suggesting such molecular signatures are at least partially linked to age-related factors.

Single-nucleus RNA sequencing performed in parallel in both human control and AD brain samples and WT and AD mouse models (5xFAD) revealed remarkably different signatures between human and mice in astrocytes, as well as in microglia and oligodendrocytes (Zhou et al. 2020). While in AD mouse astrocytes upregulate Gfap and C4b, in human AD brains astrocytes upregulate genes involved in extracellular matrix pathways including NCAN and COL5A3 and downregulate genes involved in lipid and oxidative metabolism including FABP5, HILPDA and SOD2 (Table 1) (Zhou et al. 2020). These data highlight the importance of analysing human samples to dissect molecular pathways involved in AD; direct translation from animal models could often be misleading.

Single-nucleus RNA sequencing of entorhinal cortex from human healthy and AD brains (n = 6 per group) revealed changes in specific astrocyte subpopulations (Grubman et al. 2019). While the AD astrocyte subcluster called a1 in this study upregulated genes involved in ribosomal, mitochondrial, neuron differentiation and heat shock responses, the AD astrocyte subcluster called a2 downregulated these processes and upregulated genes involved in transforming growth factor β (TGF-β) signalling and immune responses (Table 1). Upregulation of C3 was also observed in AD astrocytes from the a2 subcluster in agreement with previous bulk RNA-seq analyses (Sekar et al. 2015). When analysing the expression of 1,000 GWAS candidate genes for AD and AD-related traits, ADAMTS18, KCNN3 and BIN1 were found upregulated, whereas RGS20, FRMD4A and APOE were downregulated in AD astrocytes (Table 1). APOE was downregulated in both a1 and a2 subclusters, in agreement with previous observations in human iPSC-derived astrocytes (Lin et al. 2018), while it was upregulated in microglial AD subcluster. The transcription factor TFEB, a master regulator of lysosomal function, is upregulated in AD astrocytes; TFEB was found to drive a network of ten AD GWAS genes (BIN1, CLDN11, POLN, STK32B, EDIL3, AKAP12, HECW1, WDR5, LEMD2, and DLC1).
All these genes were dysregulated in AD astrocytes, suggesting that this master regulator controls the transition of astrocytes to a specific state identified by authors as “diseased” (Grubman et al. 2019). Single-nucleus sequencing was also performed in the prefrontal cortex of a bigger cohort of human control and AD brains (n = 24 per group) and confirmed APOE downregulation in AD astrocytes along with upregulation in microglia (Mathys et al. 2019). Subclustering of astrocyte nuclei revealed four subpopulations of cells with one subcluster called Ast1 enriched with AD cells that upregulated GLUL and the AD risk gene CLU (Mathys et al. 2019) (Table 1), previously found upregulated in reactive astrocytes in response to neurodegeneration (Shin et al. 2006). Recent single-nucleus sequencing of the entorhinal cortex and the superior frontal gyrus from human healthy brains (n = 3), early (n = 4) and advanced (n = 3) stages of AD also revealed an astrocyte subpopulation expressing higher levels of GFAP, called GFAP-high (Leng et al. 2021). GFAP-high astrocytes upregulate CD44 and TNC, both involved in interactions with the extracellular matrix; as well as HSPB1 and HSP90AA1, chaperones involved in proteostasis. Interestingly, GFAP-high astrocytes downregulated genes involved in glutamate and GABA homeostasis (SLC1A2, SLC1A3, GLUL and SLC6A11) and synaptic adhesion/maintenance (NRXN1, CADM2, PTN and GPC5), indicating they may have compromised homeostatic function (Leng et al. 2021) (Table 1).

Overall, these studies provide complementary snapshots of astrocytic responses to pathology in the AD brain. Although there is still an acute need for more in-depth RNA sequencing analyses combined with large-scale meta-analyses on astrocyte transcriptomic datasets (Kajiwara et al. 2018), the identification of genes and transcription factors that orchestrate the conversion of control to AD-associated astrocytes can already pinpoint specific molecular processes. In the coming years, integration of the most advanced sequencing technologies i.e. spatial transcriptomics (Chen et al. 2020; Prokop et al. 2019) with multi-omics approaches i.e. epigenomics, proteomics and metabolomics (Johnson et al. 2020; Klein et al. 2020; Swarup et al. 2020) will allow validation of the present findings and provide specific mechanisms for therapeutic intervention.

### Table 1. Summary of differentially expressed genes (DEGs) and molecular pathways based on RNA sequencing analysis of astrocytes in Alzheimer’s disease. DEGs are shown comparing AD vs control mice and human healthy vs AD patient brain samples. Upregulated genes are shown in red, downregulated genes in blue and dysregulated genes in green.

| Species     | Brain region | RNA-seq Technique | Isolation method | DEGs                  | Pathways                                | Refs                  |
|-------------|--------------|-------------------|------------------|-----------------------|-----------------------------------------|-----------------------|
| Mouse APP/P S1 | Cortex       | Bulk RNA-seq     | GLT-1            | Cst7, Ccl4, Il1b, Clec7a, Tyrobo, Hes5, Tm7sf2, Cyp5t, Mvd | Inflammatory response; Neuronal support; Cholesterol biosynthesis | (Orre et al. 2014)    |
| Mouse PS2A PP  | Cortex       | Bulk RNA-seq     | GFAP             | Gfap, Bcl3, Serpina3n, C4a, C4b |                                         | (Srinivasan et al. 2016) |
| Species       | Region               | Data Type   | Genes                          | Functions                                      | References                |
|--------------|----------------------|-------------|--------------------------------|------------------------------------------------|
| Mouse        | APP/P S1 Whole brain| Bulk RNA-seq| ACSA2 Cyb5r2 Chil4 Bdkrb2 Rnase4 C4b | Cytoskeleton; Cell signaling; Cytoskeleton; Cell junctions |
| Human        | Lateral temporal cortex | Microarray GFAP | MYO6 KIF21A ACTNB IGF1R PIK3R1 MAP3K12 GJC1 ZO1 TJAP1 | Cytoskeleton; Cell signaling; Cell junctions |
| Human        | Parietal cortex      | Bulk RNA-seq unbiased | ACOT1 ACOT2 TRMT61B FASTKD2 NDUFA4L2 CLU C3 CD74 | Lipid metabolism |
| Human        | Posterior cingulate cortex | Bulk RNA-seq ALDH1L1 | Gfap Serpina3n Apoe Clu Ctsb Ctsd Ctsl | Disease associated astrocytes (DAA) cluster |
| Mouse        | Hippocampus         | Single-nuclei unbiased | Gfap C4b NCAN COL5A3 | Extracellular matrix; Lipid and oxidative metabolism |
| Mouse        | Cortex              | Single-nuclei unbiased | FABP5 HILPDA SOD2 C3 ADAMTS18 KCNN3 BIN1 TFE2 | Extracellular matrix; Lipid and oxidative metabolism |
| Human        | Prefrontal cortex   | Single-nuclei unbiased | RGS20 FRMD4A APOE CLDN1 POLN STK32B EDIL3 AKAP12 | Ribosomal function; Mitochondrial function; Neuron differentiation; Heat shock responses; TGFβ signaling; Immune response |
| Human        | Entorhinal cortex   | Single-nuclei unbiased | C3 ADAMTS18 KCNN3 BIN1 TFE2 | Ribosomal function; Mitochondrial function; Neuron differentiation; Heat shock responses; TGFβ signaling; Immune response |

(Pan et al., 2020) (Simpson et al. 2011) (Mills et al. 2013) (Sekar et al. 2015) (Habib et al. 2020) (Zhou et al. 2020) (Grubman et al. 2019)
4. CONCLUSIONS AND FUTURE DIRECTIONS

Astrocytes have multiple functions in the brain and are essential for protection of neurons and maintenance of homeostasis. However, under different pathological conditions including AD, they acquire diverse states, associated with either gain or loss of function contributing to neuroinflammation and neurodegeneration (Fig. 3). A complete description of these cellular states, including multi-omics approaches combined with morphological and functional analyses, will advance understanding of how astrocytes evolve in pathology and in the near future, we may be able to relate different astroglial states to specific stages of AD, which might lead to novel biomarkers and targets for therapeutic intervention.

Funding: This work was supported by the FEDER/Ministerio de Ciencia e Innovación - Agencia Estatal de Investigación grant RTI2018-101850-A-I00 to AMA (Spain), and a start-up grant from the IKERBASQUE Basque Foundation of Science to AMA.

Acknowledgements: Confocal microscopy was performed in the VIB Bio Imaging Core and the Achucarro Imaging Core. We thank Laura Escobar for technical assistance.

Author contributions: P.P., M.A.T., and A.M.A. participated in the initial discussion and drafted the outline. P.P., M.A.T., A.V. and A.M.A. prepared the figures, and P.P. and A.M.A prepared the table. All authors wrote parts of the manuscript, edited, and improved accuracy. All authors have approved the final version of the manuscript.

Conflict of interests: Authors declare that they have no competing interests.
REFERENCES

Agulhon, C., Sun, M.-Y., Murphy, T., Myers, T., Lauderdale, K., and Fiacco, T. 2012. “Calcium Signaling and Gliotransmission in Normal vs. Reactive Astrocytes.” Frontiers in Pharmacology 3:139.

Alami, N. O., Schurr, C., Heuvel, F. O., Tang, L., Li, Q., Tasdogan, A., Kimbara, A., Nettekoven, M., Ottaviani, G., Raposo, C., Röver, S., Rogers-Evans, M., Rothenhäusler, B., Ullmer, C., Fingerle, J., Grether, U., Knuesel, I., Boeckers, T. M., Ludolph, A., Wirth, T., Roselli, F. and, Baumann, B. 2018. “NF-κB Activation in Astrocytes Drives a Stage-specific Beneficial Neuroimmunological Response in ALS.” The EMBO Journal 37(16):e98697

Alberdi, E., Wyssenbach, A., Alberdi, M., Sanchez-Gomez, M.V., Cavaliere, F., Rodriguez, J.J., Verkhratsky, A., and Matute, C. 2013. “Ca(2+) -dependent endoplasmic reticulum stress correlates with astrogliosis in oligomeric amyloid beta-treated astrocytes and in a model of Alzheimer's disease.” Aging Cell 12, 292-302.

Allen, N. J., and Eroglu, C. 2017. “Cell Biology of Astrocyte-Synapse Interactions.” Neuron 96(3):697–708.

Arranz, A. M., and De Strooper, B. 2019. “The Role of Astroglia in Alzheimer’s Disease: Pathophysiology and Clinical Implications.” The Lancet Neurology 18(4):406–414.

Baldwin, K. T., and Eroglu, C. 2017. “Molecular Mechanisms of Astrocyte-Induced Synaptogenesis.” Current Opinion in Neurobiology 45:113–120.

Batiuk, M. Y., Martirosyan, A., Wahis, J., de Vin, F., Marneffe, C., Kusserow, C., Koeppen, J., Viana, J.F., Oliveira, J. F., Voet, T., Ponting, C. P., Belgard, T. M., and Holt, M. J. 2020. “Identification of Region-Specific Astrocyte Subtypes at Single Cell Resolution.” Nature Communications 11(1):1–15.

Bayraktar, O. A., Bartels, T., Holmqvist, S., Kleshchevnikov, V., Martirosyan, A., Polioudakis, D., Ben Haim, L., Young, A. M. H., Batiuk, M. Y., Prakash, K., Brown, A., Roberts, K., Paredes, M. F., Kawaguchi, R., Stockley, J. H., Sabeur, K., Chang, S. M., Huang, E., Hutchison, P., … Rowitch, D. H. 2020. “Astrocyte Layers in the Mammalian Cerebral Cortex Revealed by a Single-Cell in Situ Transcriptomic Map.” Nature Neuroscience 23(4):500–509.

Beach, T. G., and E. G. McGeer, E. G. 1988. “Lamina-Specific Arrangement of Astrocytic Gliosis and Senile Plaques in Alzheimer's Disease Visual Cortex.” Brain Research 463(2):357–361.

Beauquis, J., Vinuesa, A., Pomilio, C., Pavia, P., Galván, V., and Saravia, F. 2014. “Neuronal and Glial Alterations, Increased Anxiety, and Cognitive Impairment before Hippocampal Amyloid Deposition in PDAPP Mice, Model of Alzheimer's Disease.” Hippocampus 24(3):257-269.

Bushong, E. A., Martone, M. E., Jones, Y. Z., and Ellisman, M. H. 2002. “Protoplasmic Astrocytes in CA1 Stratum Radiatum Occupy Separate Anatomical Domains.” Journal of Neuroscience 22(1):183–192.

Carter, S. F., Scholl, M., Almkvist, O., Wall, A., Engler, H., Langstrom, B., and Nordberg, A. 2012. “Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11C-Deuterium-L-Deprenyl: A Multi-tracer PET Paradigm Combining 11C-Pittsburgh Compound B and 18F-FDG.” Journal of Nuclear Medicine 53(1):37–46.

Chai, H., Diaz-Castro, B., Shigetomi, E., Monte, E., Octeau, J. c., Yu, X., Cohn, W., Rajendran, P.- S., Vondriska, T. M., Whitelegge, J. P., Coppola, G., and Khakh, B. S, 2017. “Neural Circuit-Specialized Astrocytes: Transcriptomic, Proteomic, Morphological, and Functional Evidence.” Neuron 95(3):531-549.

Chen, A., Akinyemi, R.O., Hase, Y., Firbank, M.J., Okamoto, Y., Thomas, A.J., Polvikoski, T.M., Allan, L.M., Oakley, A.E., O'Brien, J.T., Horsburgh, K., Ihara, M., and Kalaria, R.N. 2016. “Frontal white matter hyperintensities, clasmatodendrosis and gliovascular abnormalities in ageing and post-stroke dementia.” Brain 139, 242-258.
Chen, W.-T., Lu, A., Craessaerts, K., Pavie, B., Frigerio, C. S., Corthout, N., Qian, X., Laláková, J., Kühnemund, M., Voytyuk, I., Wolfs, L., Mancuso, R., Salta, E., Balusu, S., Snellinx, A., Munck, S., Jurek, A., Fernandez Navarro, J., Saido, T. C., ... De Strooper, B. 2020. “Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease.” Cell 182(4):976-991.

Chun, H., Im, H., Kang, Y.J., Kim, Y., Shin, J.H., Won, W., Lim, J., Ju, Y., Park, Y.M., Kim, S., Lee, S.E., Lee, J., Woo, J., Hwang, Y., Cho, H., Jo, S., Park, J.H., Kim, D., Kim, D.Y., ... and Lee, C.J. 2020. “Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer’s disease via H2O2(-) production.” Nature Neuroscience 23: 1555-1566.

Chvátal, A., and Verkhratsky, A. 2018. “An Early History of Neuroglial Research: Personalities.” Neuroglia 1(1):245–281.

Colombo, J. A., Quinn, B., and Puissant, V. 2002. “Disruption of Astroglial Interlaminar Processes in Alzheimer’s Disease.” Brain Research Bulletin 58(2):235–242.

Di Giorgio, F. P., Carrasco, M. A., Siao, M. S., Maniatis, T., and Eggan, K. 2007. “Non-Cell Autonomous Effect of Glia on Motor Neurons in an Embryonic Stem Cell-Based ALS Model.” Nature Neuroscience 10(5):608–614.

Diaz-Castro, B., Gangwani, M. R., Yu, X., Coppola, G., and Khakh, B. S. 2019. “Astrocyte Molecular Signatures in Huntington’s Disease.” Science Translational Medicine 11(514):1–13.

Dimou, L., Simon, C., Kirchhoff, F., Takebayashi, H., and Götz, M. 2008. “Progeny of Olig2-Expressing Progenitors in the Gray and White Matter of the Adult Mouse Cerebral Cortex.” Journal of Neuroscience 28(41):10434–10442.

Diniz, L. P., Tortelli, V., Matias, I., Morgado, J., Araujo, A. P. B., Melo, H. M., da Silva, G. S. S., Alves-Leon, S. V., de Souza, J. M., Ferreira, S. T., de Felice, F. G., and Gomes, F. C. A. 2017. “Astrocyte Transforming Growth Factor Beta 1 Protects Synapses against Aβ Oligomers in Alzheimer’s Disease Model.” Journal of Neuroscience 37(28):6797–6809.

Du, X., Zhang, Z., Zhou, H., and Zhou, J. 2020. “Differential Modulators of NG2-Glia Differentiation into Neurons and Glia and Their Crosstalk.” Cellular and Molecular Neurobiology 41(1):1-15.

Dubois, B., Hampel, H., Feldman, H. H., Scheitens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennoe, K., Broich, K., Cavedo, E., Crutch, S., Duyckaerts, C., Frisoni, G. B., Gauthier, S., Gauthier, R., Gouw, A. A., Habert, M., ... Working, I. 2016. “Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria.” Alzheimers Dementia 12(3):292-323.

Escartin, C., Galea, E., Lakatos, A., O’Callaghan, J.P., Petzold, G.C., Serrano-Pozo, A., Steinhauser, C., Volterra, A., Carmignoto, G., Agarwal, A., Allen, N.J., Araque, A., Louis Barbeito, L., Barzilai, A., Bergles, D.E., Bonvento, G., Butt, A.M., Chen, W.-T., Cohen-Salmon, M., ... Verkhratsky, A. 2021. “Working consensus on reactive astrocyte nomenclature, definitions and future directions.” Nature Neuroscience.

Escartin, C., Guillemaud, O., and Carrillo-de Sauvage, M. A. 2019. “Questions and (Some) Answers on Reactive Astrocytes.” GLIA 67(12):2221–2247.

Falcone, C., Penna, E., Hong, T., Tarantal, A. F., Hof, P. R., Hopkins, W. D., Sherwood, C. C., Noctor, S. C., and Martínez-Cerdeño, V. 2021. “Cortical Interlaminar Astrocytes Are Generated Prenatally, Mature Postnatally, and Express Unique Markers in Human and Nonhuman Primates.” Cerebral Cortex (New York, N.Y.: 1991) 31(1):379–395.

Freeman, M. R. 2010. “Specification and Morphogenesis of Astrocytes.” American Association for the Advancement of Science 330:774-778.

Frere, S., and Slutsky, I. 2018. “Alzheimer’s Disease: From Firing Instability to Homeostasis Network Collapse.” Neuron 97(1):32–58.
Frost, G. R., and Li, Y.-M. 2017. “The Role of Astrocytes in Amyloid Production and Alzheimer’s Disease.” Open Biology 7(12):170228.

Garaschuk, O., and Verkhratsky, A. 2019. “GABAergic astrocytes in Alzheimer's disease.” Aging 11:1602-1604.

Ge, W. P., Miyawaki, A., Gage, F. H., Jan, Y. N., & Jan, L. Y. 2012. “Local Generation of Glia Is a Major Astrocyte Source in Postnatal Cortex.” Nature 484(7394):376–380.

Ghatak, S., Dolatabadi, N., Trudler, D., Zhang, X., Wu, Y., Mohata, M., Ambasudhan, R., Talantova, M., and Lipton, S.A. 2019. “Mechanisms of hyperexcitability in Alzheimer’s disease hiPSC-derived neurons and cerebral organoids vs isogenic controls.” Elife 8:e50333.

Gomes, W. A., Mehler, M. F., and Kessler, J. A. 2003. “Transgenic Overexpression of BMP4 Increases Astroglial and Decreases Oligodendroglial Lineage Commitment.” Developmental Biology 255(1):164–177.

Gomez-Arboledas, A., Davila, J. C., Sanchez-Mejias, E., Navarro, V., Nuñez-Diaz, C., Sanchez-Varo, R., Sanchez-Mico, M. V., Trujillo-Estrada, L., Fernandez-Valenzuela, J. J., Vizuete, M., Comella, J. X., Galea, E., Vitorica, J., and Gutierrez, A. 2018. “Phagocytic Clearance of Presynaptic Dystrophies by Reactive Astrocytes in Alzheimer’s Disease.” Glia 66(3):637–653.

Gross, R. E., Mehler, M. F., Mabie, P. C., Zang, Z., Santschi, L., and Kessler, J. A. 1996. “Bone Morphogenetic Proteins Promote Astroglial Lineage Commitment by Mammalian Subventricular Zone Progenitor Cells.” Neuron 17(4):595–606.

Gu, X.-L., Long, C.-X., Sun, L., Xie, C., Lin, X., and Cai, H. 2010. “Astrocytic Expression of Parkinson’s Disease-Related A53T-Synuclein Causes Neurodegeneration in Mice.” Molecular Brain 3(1):12.

Guillemot, F. 2007. “Cell Fate Specification in the Mammalian Telencephalon.” Progress in Neurobiology 83(1):37–52.

Habib, N., McCabe, C., Medina, S., Varshavsky, M., Kitsberg, D., Dvir-Szternfeld, R., Green, G., Dionne, D., Nguyen, L., Marshall, J. L., Chen, F., Zhang, F., Kaplan, T., Regev, A., and Schwartz, M. 2020. “Disease-Associated Astrocytes in Alzheimer’s Disease and Aging.” Nature Neuroscience 23(6):701–706.

He, F., Ge, W., Martinowich, K., Becker-Catania, S., Coskun, V., Zhu, W., Wu, H., Castro, D., Guillemot, F., Fan, G., De Vellis, J., and Sun, Y. E. 2005. “A Positive Autoregulatory Loop of Jak-STAT Signaling Controls the Onset of Astrogligenesis.” Nature Neuroscience 8(5):616–625.

Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., and Paul, S. M. 2000. “Apolipoprotein E Isoform-Dependent Amyloid Deposition and Neuritic Degeneration in a Mouse Model of Alzheimer’s Disease.” Proceedings of the National Academy of Sciences 97(6):2892–2897.

Hsu, E. T., Gangolli, M., Su, S., Holleran, L., Stein, T. D., Alvarez, V. E., McKee, A. C., Schmidt, R. E., and Brody, D. L. 2018. “Astrocytic Degeneration in Chronic Traumatic Encephalopathy.” Acta Neuropathologica 36(6):955–972.

Huynh, T. P. V., Liao, F., Francis, C. M., Robinson, G. O., Serrano, J. R., Jiang, H., Roh, J., Finn, M. B., Sullivan, P. M., Esparza, T. J., Stewart, F. R., Mahan, T. E., Ulrich, J. D., Cole, T., and Holtzman, D. M.
2017. “Age-Dependent Effects of ApoE Reduction Using Antisense Oligonucleotides in a Model of β-Amyloidosis.” Neuron 96(5):1013-1023.

Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., Nagelhus, E. A., and Nedergaard, M. 2012. “A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid B.” Science Translational Medicine 15;4(147):147ra111.

Iram, T., Trudler, D., Kain, D., Kanner, S., Galron, R., Vassar, R., Barzilai, A., Blinder, P., Fishelson, Z., and Frenkel, D. 2016. “Astrocytes from Old Alzheimer’s Disease Mice Are Impaired in Aβ Uptake and in Neuroprotection.” Neurobiology of Disease 96:84-94.

Jahn, H. M., Kasakow, C. V., Helfer, A., Michely, J., Verkhratsky, A., Maurer, H. H., Scheller, A., and Kirkhoff, F. 2018. “Refined Protocols of Tamoxifen Injection for Inducible DNA Recombination in Mouse Astroglia.” Scientific Reports 8(1):1-11.

Jo, S., Yarishkin, O., Hwang, Y.J., Chun, Y.E., Park, M., Woo, D.H., Bae, J.Y., Kim, T., Lee, J., Chun, H., Park, H.J., Lee, D.Y., Hong, J., Kim, H.Y., Oh, S.J., Park, S.J., Lee, H., Yoon, B.E., Kim, Y., … and Lee, C.J. 2014. “GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease.” Nature Medicine 20:886-896.

John Lin, C. C., Yu, K., Hatcher, A., Huang, T. W., Lee, H. K., Carlson, J., Weston, M. C., Chen, F., Zhang, Y., Zhu, W., Mohila, C. A., Ahmed, N., Patel, A. J., Arenkiel, B. R., Noebels, J. L., Creighton, C. J., and Deneen, B. 2017. “Identification of Diverse Astrocyte Populations and Their Malignant Analogs.” Nature Neuroscience 20(3):396-405.

Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., Thambisetty, M., Montine, T. J., Lee, E. B., Trojanowski, J. Q., Beach, T. G., Reiman, E. M., Haroutunian, V., Wang, M., Schadt, E., … Seyfried, N. T. 2020. "Large-Scale Proteomic Analysis of Alzheimer’s Disease Brain and Cerebrospinal Fluid Reveals Early Changes in Energy Metabolism Associated with Microglia and Astrocyte Activation.” Nature Medicine 26(5):769-780.

Jones, V. C., Atkinson-Dell, R., Verkhratsky, A., and Mohamet, L. 2017. “Aberrant IPSC-Derived Human Astrocytes in Alzheimer’s Disease.” Cell Death & Disease 8(3):e2696.

Julia, T. C. W., Liang, S. A., Qian, L., Pipalia, N. H., Chao, M. J., Shi, Y., Bertelsen, S. E., Kapoor, M., Mcarora, E., Sikora, E., Holtzman, D. M., Maxfield, F. R., Zhang, B., Wang, M., Poon, W. W., and Goate, A. M. 2019. “Cholesterol and Matrisome Pathways Dysregulated in Human APOE E4 Glia.” BioRxiv 713362.

Kanj, Y.-J., and Chung, W.-S. 2018. “Phagocytic Roles of Glial Cells in Healthy and Diseased Brains.” Biomolecules & Therapeutics 8:1-8.

Kajiwara, Y., Wang, E., Wang, M., Sin, W. C., Brennand, K. J., Schadt, E., Naus, C. C., Buxbaum, J., and Zhang, B. 2018. "GJA1 (Connexin43) Is a Key Regulator of Alzheimer’s Disease Pathogenesis." Acta Neuropathologica Communications 6(1):144.

Kanski, R., Van Strien, M. E., Van Tijn, P., and Hol, E. M. 2014. “A Star Is Born: New Insights into the Mechanism of Astrogenesis.” Cellular and Molecular Life Sciences 71(3):433-447.

Keller, D., Erö, C., and Markram, H. 2018. “Cell Densities in the Mouse Brain: A Systematic Review.” Frontiers in Neuroanatomy 12:83.

Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., Itzkovitz, S., Colonna, M., Schwartz, M., and Amit, I. 2017. “A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease.” Cell 169(7):1276-1290.

Kettenmann, H., and Verkhratsky, A. 2013. “Glial cells. In Neuroscience in the 21st Century: From Basic to Clinical.” Springer New York pp. 475–506.
Klein, H. U., Schäfer, M., Bennett, D. A., Schwender, H., and de Jager, P. L. 2020. “Bayesian Integrative Analysis of Epigenomic and Transcriptomic Data Identifies Alzheimer’s Disease Candidate Genes and Networks.” PLoS Computational Biology 16(4):e10007771.

Kraft, A. W., Hu, X., Yoon, H., Yan, P., Xiao, O., Wang, Y., Gil, S. H., Brown, J., Wilhelmsson, U., Restivo, J. L., Cirrito, J. R., Holtzman, D. M., Kim, J., Pekny, M., and Lee, J. M. 2013. “Attenuating Astrocyte Activation Accelerates Plaque Pathogenesis in APP/PS1 Mice.” FASEB Journal 27(1):187–198.

Krencik, R., van Asperen, J. V., and Ullian, E. M. 2017. “Human Astrocytes Are Distinct Contributors to the Complexity of Synaptic Function.” Brain Research Bulletin 129:66–73.

Kuchibhotla, K. V., Lattarulo, C. R., Hyman, B. T., and Bacskaik, B. J. 2009. “Astrocytes in Alzheimer.” Science 323:1143-1143.

Lanjakornsiripan, D., Pior, B. J., Kawaguchi, D., Furutachi, S., Tahara, T., Katsuyama, Y., Suzuki, Y., Fukazawa, Y., and Gotoh, Y. 2018. “Layer-Specific Morphological and Molecular Differences in Neocortical Astrocytes and Their Dependence on Neuronal Layers.” Nature Communications 9(1):1623.

Lee, J.-H., Kim, J.-Y., Noh, S., Lee, H., Lee, S. Y., Mun, J. Y., Park, H., and Chung, W-S. 2020. “Astrocytes Phagocytose Adult Hippocampal Synapses for Circuit Homeostasis.” Nature.

Leng, K., Li, E., Eser, R., Piergies, A., Sit, R., Tan, M., Neff, N., Li, S. H., Rodriguez, R. D., Suemoto, C. K., Leite, R. E. P., Ehrenberg, A. J., Pasqualucci, C. A., Seeley, W. W., Spina, S., Heinsen, H., Grinberg, L. T., and Kampmann, M. 2021. “Molecular characterization of selectively vulnerable neurons in Alzheimer’s disease”. Nature Neuroscience.

Lian, H., and Zheng, H. 2016. “Signaling Pathways Regulating Neuron-Glia Interaction and Their Implications in Alzheimer’s Disease.” Journal of Neurochemistry 136(3):475-491.

Lian, H., Yang, L., Cole, A., Sun, L., Chiang, A. C. A., Fowler, S. W., Shim, D. J., Rodriguez-Rivera, J., Tagliatela, G., Jankowsky, J. L., Lu, H. C., and Zheng, H. 2015. “NFkB-Activated Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function Associated with Alzheimer’s Disease.” Neuron 85(1):101-115.

Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., Wilton, D. K., Frouin, A., Napier, B. A., Panicker, N., Kumar, M., Buckwalter, M. S., Rowitch, D. H., Dawson, V. L., Dawson, T. M., … Barres, B. A. 2017. “Neurotoxic Reactive Astrocytes Are Induced by Activated Microglia.” Nature 541(7638):481-487.

Liebner, S., Dijkhuizen, R. M., Reiss, Y., Plate, K. H., Agalliu, D., and Constantin, G. 2018. “Functional Morphology of the Blood–Brain Barrier in Health and Disease.” Acta Neuropathologica 135(3):311–336.

Lin, Y.-T., Geo, F., Feldman, H. M., Wen, H.-L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., Rueda, R., Kritskiy, O., Abdurrob, F., Peng, Z., Milo, B., Yu, C. J., Elmsaouri, S., Dey, D., Ko, T., … Tsai, L.-H. 2018. “APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer’s Disease PHENOTYPES in Human IPSC-Derived Brain Cell Types.” Neuron 98(6):1141-1154.

Liu, C. C., Zhao, N., Fu, Y., Wang, N., Linares, C., Tsai, C. W., and Bu, G. 2017. “ApoE4 Accelerates Early Seeding of Amyloid Pathology.” Neuron 96(5):1024-1032.

Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., Martorell, A. J., Ransohoff, R. M., Hafler, B. P., Bennett, D. A., Kellis, M., and Tsai, L. H. 2019. “Single-Cell Transcriptomic Analysis of Alzheimer’s Disease.” Nature 570(7761):332–337.

Mills, J. D., Nalpathamkalam, T., Jacobs, H. I. L., Janitz, C., Merico, D., Hu, P., and Janitz, M. 2013. “RNA-Seq Analysis of the Parietal Cortex in Alzheimer’s Disease Reveals Alternatively Spliced Isoforms Related to Lipid Metabolism.” Neuroscience Letters 536(1):90–95.
Molofsky, A. V., and Deneen, B. 2015. “Astrocyte Development: A Guide for the Perplexed.” GLIA 63(8):1320–1329.

Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicanu, M., Joe, E., Nelson, A. R., D’Orazio, L. M., Buennagel, D. P., Harrington, M. G., Benzinger, T. L. S., Fagan, A. M., Ringman, J. M., Schneider, L. S., Morris, J. C., Reiman, E. M., Caselli, R. J., Chui, H. C., Tcw, J., Chen, Y., Pa, J., Conti, P. S., Law, M., Toga, A. W., and Zlokovic, B. V. 2020. “APOE4 Leads to Blood–Brain Barrier Dysfunction Predicting Cognitive Decline.” Nature 581(7806):71–76.

Morel, L., Chiang, M. S. R., Higashimori, H., Shoneye, T., Iyer, L. K., Yelick, J., Tai, A., and Yang, Y. 2017. “Molecular and Functional Properties of Regional Astrocytes in the Adult Brain.” Journal of Neuroscience 37(36):8706–8717.

Nakashima, K., Takizawa, T., Ochiai, W., Yanagisawa, M., Hisatsune, T., Nakafuku, M., Miyazono, K., Kishimoto, T., Kageyama, R., and Taga, T. 2001. “BMP2-mediated alteration in the developmental pathway of fetal mouse brain cells from neurogenesis to astrocytogenesis.” Proceedings of the National Academy of Sciences 98:5868–5873.

Nakashima, K., Yanagisawa, M., Arakawa, H., and Taga, T. 1999. “Astrocyte Differentiation Mediated by LIF in Cooperation with BMP2.” FEBS Letters 457(1):43–46.

Nedergaard, M. 2013. “Garbage Truck of the Brain.” Science 340(6140):1529–1530.

Nortley, R., and Attwell, D. 2017. “Control of Brain Energy Supply by Astrocytes.” Current Opinion in Neurobiology 47:80–85.

Oberheim, N. A., Takano, T., Han, X., He, W., Lin, J. H. C., Wang, F., Xu, Q., Wyatt, J. D., Pilcher, W., Ojemann, J. G., Ransom, B. R., Goldman, S. A., and Nedergaard, M. 2009. “Uniquely Hominid Features of Adult Human Astrocytes.” Journal of Neuroscience 29(10):3276–3287.

Oberheim, N. A., Wang, X., Goldman, S., and Nedergaard, M. 2006. “Astrocytic Complexity Distinguishes the Human Brain.” Trends in Neurosciences 29(10):547–553.

Olabarria, M., Noristani, H. N., Verkhratsky, A., and Rodríguez, J. J. 2011. “Age-Dependent Decrease in Glutamine Synthetase Expression in the Hippocampal Astroglia of the Triple Transgenic Alzheimer’s Disease Mouse Model: Mechanism for Deficient Glutamatergic Transmission?” Molecular Neurodegeneration 6(1):55.

Orre, M., Kamphuis, W., Osborn, L. M., Jansen, A. H. P., Kooijman, L., Boskers, K., and Hol, E. M. 2014. “Isolation of Glia from Alzheimer’s Mice Reveals Inflammation Anddysfunction.” Neurobiology of Aging 35(12):2746–2760.

Pan, J., Ma, N., Yu, B., Zhang, W., and Wan, J. 2020. “Transcriptomic Profiling of Microglia and Astrocytes throughout Aging.” Journal of Neuroinflammation 17(1): 97.

Pellerin, L., and Magistretti, P. J. 2012. “Sweet Sixteen for ANLS.” Journal of Cerebral Blood Flow and Metabolism 32(7):1152–1166.

Pelvig, D. P., Pakkenberg, H., Stark, A. K., and Pakkenberg, B. 2008. “Neocortical Glial Cell Numbers in Human Brains.” Neurobiology of Aging 29(11):1754–1762.

Pereira, D. L., Tortelli, V., Matias I., Morgado, J., Araujo, A. P. B., Melo, H. M., da Silva, G. S. S., Alves-leon, S. V., De Souza, J. M., Ferreira, S. T., de Felice, F. G., and Gomes, F. C. A. 2017. “Astrocyte Trans-
forming Growth Factor Beta 1 Protects Synapses against Aβ Oligomers in Alzheimer's Disease Model.” 37(28):6797–6809.

Polis, B., Srikanth, K. D., Elliott, E., Gil-Henn, H., and Samson, A. O. 2018. “L-Norvaline Reverses Cognitive Decline and Synaptic Loss in a Murine Model of Alzheimer’s Disease.” Neurotherapeutics 15(4):1036–1054.

Prokop, S., Miller, K. R., Labra, S. R., Pitkin, R. M., Hoxha, K., Narasimhan, S., Changolkar, L., Rosenbloom, A., Lee, V. M. Y., and Trojanowski, J. Q. 2019. “Impact of TREM2 Risk Variants on Brain Region-Specific Immune Activation and Plaque Microenvironment in Alzheimer’s Disease Patient Brain Samples.” Acta Neuropathologica 138(4):613–630.

Qin, S., Niu, W., Iqbal, N., Smith, D. K., and Zhang, C. L. 2014. “Orphan Nuclear Receptor TLX Regulates Astrogenesis by Modulating BMP Signaling.” Frontiers in Neuroscience 8(74).

Ramón y Cajal, S. 1913. “ Contribución Al Conocimiento de La Neuroglia Del Cerebro Humano.” Trab. Lab. Invest. Biol. Univ. Madrid pp. 255–315.

Ries, M., and Sastre, M. 2016. “Mechanisms of Aβ Clearance and Degradation by Glial Cells.” Frontiers in Aging Neuroscience 8:1–9.

Rodriguez-Vieitez, E., Ni, R., Gulyás, B., Tóth, M., Häggkvist, J., Halldin, C., Voytenko, L., Marutle, A., and Nordberg, A. 2015. “Astrocytosis Precedes Amyloid Plaque Deposition in Alzheimer APPswe Transgenic Mouse Brain: A Correlative Positron Emission Tomography and in Vitro Imaging Study.” European Journal of Nuclear Medicine and Molecular Imaging 42(7):1119–1132.

Rodriguez-Vieitez, E., Saint-Aubert, L., Carter, S. F., Almkvist, O., Farid, K., Schöll, M., Chiotsis, K., Thordardottir, S., Graff, C., Wall, A., Långström, B., and Nordberg, A. 2016. “ Diverging Longitudinal Changes in Astrocytosis and Amyloid PET in Autosomal Dominant Alzheimer’s Disease.” Brain 139(3):922–936.

Rodríguez, J. J., Olabarria, M., Chvatal, A., and Verkhratsky, A. 2009. “Astrogia in Dementia and Alzheimer’s Disease.” Cell Death & Differentiation 16(3):378–385.

Rose, C. R., and Verkhratsky, A. 2016. “Principles of Sodium Homeostasis and Sodium Signalling in Astroglia.” Glia 64(10):1611–1627.

Schitine, C., Nogaroli, L., Costa, M. R., and Hedin-Pereira, C. 2015. “Astrocyte Heterogeneity in the Brain: From Development to Disease.” Frontiers in Cellular Neuroscience 9(76).

Scholl, M., Carter, S. F., Westman, E., Rodríguez-Vieitez, E., Almkvist, O., Thordardottir, S., Wall, A., Graff, C., Långström, B., and Nordberg, A. 2015. “Early Astrocytosis in Autosomal Dominant Alzheimer’s Disease Measured in Vivo by Multi-Tracer Positron Emission Tomography.” Scientific Reports 5:1–14.

Sekar, S., McDonald, J., Cuyugan, L., Aldrich, J., Kurdoglu, A., Adkins, J., Serrano, G., Beach, T. G., Craig, D. W., Valla, J., Reiman, E. M., and Liang, W. S. 2015. “Alzheimer’s Disease Is Associated with Altered Expression of Genes Involved in Immune Response and Mitochondrial Processes in Astrocytes.” Neurobiology of Aging 36(2):583–591.

Selkoe, D. J., and Hardy, J. 2016. “The Amyloid Hypothesis of Alzheimer’s Disease at 25 Years.” EMBO Molecular Medicine 8(6):595–608.

Serrano-Pozo, A., Muzikansky, A., Gómez-Isla, T., Growdon, J. H., Betensky, R. A., Frosch, M. P., and Hyman, B. T. 2013. “Differential Relationships of Reactive Astrocytes and Microglia to Fibrillar Amyloid Deposits in Alzheimer Disease.” Journal of Neuropathology and Experimental Neurology 72(6):462–471.

Sherwood, C. C., Stimpson, C. D., Raghanti, M. A., Wildman, D. E., Uddin, M., Grossman, L. I., Goodman, M., Redmond, J. C., Bonar, C. J., Erwin, J. M., and Hof, P. R. 2006. “Evolution of Increased Glia-Neuron
Ratios in the Human Frontal Cortex.” Proceedings of the National Academy of Sciences of the United States of America 103(37):13606-13611.

Shin, Y. J., Kang, S. W., Jeong, S. Y., Shim, Y. J., Kim, Y. H., Kim, B. M., Kee, S. H., Park, J. J., Park, I. S., and Min, B. H. 2006. “Clusterin Enhances Proliferation of Primary Astrocytes through Extracellular Signal-Regulated Kinase Activation.” NeuroReport 17(18):1871–1875.

Simonovitch, S., Schmukler, E., Bespalko, A., Iram, T., Frenkel, D., Holtzman, D. M., Masliah, E., Michaelson, D. M., and Pinkas-Kramarski, R. 2016. “Impaired Autophagy in APOE4 Astrocytes.” Journal of Alzheimer’s Disease 51(3):915–927.

Simpson, J. E., Ince, P. G., Shaw, P. J., Heath, P. R., Raman, R., Garwood, C. J., Gelsthorpe, C., Baxter, L., Forster, G., Matthews, F. E., Brayne, C., and Wharton, S. B. 2011. “Microarray Analysis of the Astrocyte Transcriptome in the Aging Brain: Relationship to Alzheimer’s Pathology and APOE Genotype.” Neurobiology of Aging 32(10):1795–1807.

Solano, R. M., Casarejos, M. J., Menéndez-Cuervo, J., Rodríguez-Navarro, J. A., García de Yébenes, J., and Mena, M. A. 2008. “Glial Dysfunction in Parkin Null Mice: Effects of Aging.” Journal of Neuroscience 28(3):598–611.

Sosunov, A. A., Wu, X., Tsankova, N. M., Guilfoyle, E., McKhann, G. M., and Goldman, J. E. 2014. “Phenotypic Heterogeneity and Plasticity of Isocortical and Hippocampal Astrocytes in the Human Brain.” Journal of Neuroscience 34(6):2285–2298.

Srinivasan, K., Friedman, B. A., Larson, J. L., Lauffer, B. E., Goldstein, L. D., Appling, L. L., Borneo, J., Poon, C., Ho, T., Cai, F., Steiner, P., Van Der Brug, M. P., Modrusan, Z., Kaminker, J. S., and Hansen, D. V. 2016. “Untangling the Brain’s Neuroinflammatory and Neurodegenerative Transcriptional Responses.” Nature Communications 7:11295.

Strooper, B. De, and Karran, E. 2016. “The Cellular Phase of Alzheimer’s Disease.” Cell 164(4):603–615.

Swarup, V., Chang, T. S., Duong, D. M., Dammer, E. B., Dai, J., Lah, J. J., Johnson, E. C. B., Seyfried, N. T., Levey, A. I., and Geschwind, D. H. 2020. “Identification of Conserved Proteomic Networks in Neurodegenerative Dementia.” Cell Reports 31(12).

Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., and Zlokovic, B. V. 2019. “Blood-Brain Barrier: From Physiology to Disease and Back.” Physiological Reviews 99(1):21–78.

Takizawa, T., Ochiai, W., Nakashima, K., and Taga, T. 2003. “Enhanced Gene Activation by Notch and BMP Signaling Cross-Talk.” Nucleic Acids Research 31(19):5723–5731.

Tong, X., Ao, Y., Faas, G. C., Nwaobi, S. E., Xu, J., Haustein, M. D., Anderson, M. A., Mody, I., Olsen, M. L., Sofroniew, M. V., and Khakh, B. S. 2014. “Astrocyte Kir4.1 Ion Channel Deficits Contribute to Neuronal Dysfunction in Huntington’s Disease Model Mice.” Nature Neuroscience 17(5):694–703.

Urayama, S., Semi, K., Sanosaka, T., Hori, Y., Namihira, M., Kohyama, J., Takizawa, T., and Nakashima, K. 2013. “Chromatin Accessibility at a STAT3 Target Site Is Altered Prior to Astrocyte Differentiation.” Cell Structure and Function 38 (1): 55-66.

Vasile, F., Dossi, E., and Rouach, N. 2017. “Human Astrocytes: Structure and Functions in the Healthy Brain.” Brain Structure and Function 222(5):2017–2029.

Vergheese, P. B., Castellano, J. M., Garai, K., Wang, Y., Jiang, H., Shah, A., Bu, G., Frieden, C., and Holtzman, D. M. 2013. “ApoE Influences Amyloid-β (Aβ) Clearance despite Minimal ApoE/Aβ Association in Physiological Conditions.” Proceedings of the National Academy of Sciences 110(19):1807-1816.

Verkhratsky, A, and Nedergaard, M. 2018. “Physiology of Astroglia.” Physiol Rev 98:239–389.
Verkhratsky, A. 2010. “Physiology of Neuronal-Glial Networking.” Neurochemistry International 57(4):332–343.

Verkhratsky, A., and Nedergaard, M. 2014. “Astrogial Cradle in the Life of the Synapse.” Philosophical Transactions of the Royal Society B: Biological Sciences 369(1654).

Verkhratsky, A., and Rose, C. R. 2020. “Na+-Dependent Transporters: The Backbone of Astroglial Homeostatic Function.” Cell Calcium 85: 102136.

Verkhratsky, A., Olabarria, M., Noristani, H. N., Yeh, C. Y., and Rodriguez, J. J. 2010. “Astrocytes in Alzheimer’s Disease.” Neurotherapeutics 7(4): 399-412.

Verkhratsky, A., Rodríguez-Arellano, J. J., Parpura, V., and Zorec, R. 2017. “Astrogial Calcium Signalling in Alzheimer’s Disease.” Biochemical and Biophysical Research Communications 483(4): 1005-1012.

Verkhratsky, A., Zorec, R., and Parpura, V. 2017. “Stratification of Astrocytes in Healthy and Diseased Brain.” Brain Pathology 27(5):629–644.

Verkhratsky, A., Zorec, R., Rodriguez, J. J., and Parpura, V. 2016. “Astroglia Dynamics in Ageing and Alzheimer’s Disease.” Current Opinion in Pharmacology 26:74–79.

Virchow, R. 1856. “Gesammelte Abhandlungen Zyr Wissenschaftlichen Medizin.” Frankfurt: Verlag von Meidinger Sohn & Comp.

von Bartheld, C. S., Bahney, J., and Herculano-Houzel, S. 2016. “The Search for True Numbers of Neurons and Glial Cells in the Human Brain: A Review of 150 Years of Cell Counting.” Journal of Comparative Neurology 524(18):3865–3895.

von Lennhossék. 1895. “Der Feinere Bau Des Nervensystems Im Lichte Neuester Forschung, 2nd Edn.” Berlin: Fischer’s Medicinische Buchhandlung H. Kornfield.

Wheeler, M. A., and Quintana, F. J. 2019. “Regulation of Astrocyte Functions in Multiple Sclerosis.” Cold Spring Harbor Perspectives in Medicine 9(1):a029009.

Yeh, C.Y., Vadhwana, B., Verkhratsky, A., and Rodriguez, J. J. 2011. “Early Astrocytic Atrophy in the Entorhinal Cortex of a Triple Transgenic Animal Model of Alzheimer’s Disease.” ASN Neuro 3(5): 271-279.

Yu, J.-T., Tan, L., and Hardy, J. 2014. “Apolipoprotein E in Alzheimer’s Disease: An Update.” Annual Review of Neuroscience 37(1):79–100.

Yu, X., Nagai, J., and Khakh, B. S. 2020. “Improved Tools to Study Astrocytes.” Nature Reviews Neuroscience 21(3):121–138.

Yun, S. P., Kam, T. I., Panicker, N., Kim, S., Oh, Y., Park, J. S., Kwon, S. H., Park, Y. J., Karuppagounder, S. S., Park, H., Kim, S., Oh, N., Kim, N. A., Lee, S., Brahmachari, S., Mao, X., Lee, J. H., Kumar, M., An, D., Kang, S. U., Lee, Y., Lee, K. C., Na, D. H., Kim, D., Lee, S. H., Roschke, V. V., Liddelow, S. A., Mari, Z., Barres, B. A., Dawson, V. L., Lee, S., Dawson, T. M., and Ko, H. S. 2018. “Block of A1 Astrocyte Conversion by Microglia Is Neuroprotective in Models of Parkinson’s Disease.” Nature Medicine 24(7):931-938.

Zhou, Y., Song, W. M., Andhey, P. S., Swain, A., Levy, T., Miller, K. R., Poliani, P. L., Cominelli, M., Grover, S., Gilfillan, S., Cella, M., Ulland, T. K., Zaitsev, K., Miyashita, A., Ikeuchi, T., Sainouchi, M., Kakita, A., Bennett, D. A., Schneider, J. A., … Colonna, M. 2020. “Human and Mouse Single-Nucleus Transcriptomics Reveal TREM2-Dependent and TREM2-Independent Cellular Responses in Alzheimer’s Disease.” Nature Medicine 26(1):131–142.